Human interleukin-4 (IL-4) is a small four-helix-bundle protein which is essential for organizing defense reactions against macroparasites, in particular helminths. Human IL-4 also appears to exert a pathophysiological role during various IgE-mediated allergic diseases. Seven different monoclonal antibodies neutralizing the activity of human IL-4 were studied in order to identify functionally important epitopes. A collection of 41 purified IL-4 variants was used to analyse how defined amino acid replacements affect binding affinity for each individual mAb. Specific amino acid positions could be assigned to four different epitopes. mAbs recognizing epitopes on helix A and/or C interfered with IL-4 receptor binding and thus inhibited IL-4 function. However, other mAbs also inhibiting IL-4 function recognized an epitope on helix D of IL-4 and did not inhibit IL-4 binding to the receptor protein. One mAb, recognizing N-terminal and C-terminal residues, partially competed for binding to the receptor. The results of these mAb epitope analyses confirm and extend previous data on the functional consequences of the amino acid replacements which showed that amino acid residues in helices A and C of IL-4 provide a binding site for the cloned IL-4 receptor and that a signalling site in helix D interacts with a further receptor protein.
The formation of homo-oligomers or hetero-oligomers appears to be the crucial event during activation and transmembrane signaHing of cytokine receptors (Taga et al., 1989; Miyajima et al., 1992a Miyajima et al., , 1992b Murakami et al., 1993) . For certain receptor systems oligomerisation has been shown to be mediated by different receptor-binding sites exposed on the surface of the cytok.ine Iigand. For example, human growth hormone has two binding sites promoting the formation of a homodimeric growth-hormone-receptor complex by the sequential binding of two identical receptor subunits (Cunningham et al., 1991; Ultsch et al., 1991; De Vos et al., 1992) . Mouse interleukin-2 has three binding sites allowing the formation of a heterotrimeric receptor complex consisting of an a, ß and y-subunit (Waldmann, 1991 ; Taniguchi and Minami, 1993; Voss et al., 1993) . Experiments in this study using neutralizing monoclonal antiborlies (mAbs) support the notion of the existence of two distinct functional sites in human interleukin-4 (IL-4 ).
Human IL-4 is a small four-helix-bundle protein of 129 amino acid residues that is essential for initiating defense reactions against parasites, in particular helminths (Paul, 1991; Sher and Coffman, 1992) . Human IL-4 also appears to
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Abbreviations. IL-4, interleulcin-4; EC 50 , effector concentration resulting in half-maximal response; Rmax• maximal response obtained at saturation Ievels; IC 50 , concentration resulting in half-maximal inhibition; IL-4Reu soluble IL-4 receptor; [K61Q]IL-4, interleukin-4 in which Iysine at position 61 has been replaced by glutamine. exert a pathophysiological role during IgE-mediated allergic diseases (Finkelman et al., 1990; Romagnani, 1990) . Recently, a series of human IL-4 variants has been generated by in vitro mutagenesis (Kruse et al., 1991 (Kruse et al., , 1992 (Kruse et al., , 1993 . Analysis of bioactivity and receptor binding revealed the occurrence of variants affected in IL-4 receptor binding (characterized by an increased concentration affecting the halfmaximal response, EC 50 ) and variants affected in receptor activation (characterized by a reduced maximal response obtained at saturation Ievels, Rmax). The EC 50 variants had been modified at amino acid positions in helices A and C, whereas the Rmax variants originated from arnino acid Substitutions in helix D. Thus, two functionally distinct sites appear to be present in human IL-4 which might promote the formation of the activated receptor oligomer.
The binding site and the activation site in human IL-4 should also be detected and defined by analysing the epitopes recognized by monoclonal antiborlies (mAbs) neutralizing the bioactivity. Such mAbs have been generated by several groups, since they represent important analytical tools for dissecting the function and biosynthesis of IL-4 (Ohara and Paul, 1985; Chretien et al., 1989; Solari et al., 1989) . Furthermore, they are of potential therapeutic use as IL-4 antagonists in vivo (Tepper et al., 1989 (Tepper et al., , 1990 Urban et al., 1991) .
The seven IL-4 neutralizing mAbs used in the present study were analysed by means of 41 purified IL-4 variants modified at defined single amino acid positions. Altered binding affinities between certain combinations of mAbs and IL-4 variants allowed the localization of at least four different binding regions. Epitopes on helices C and D of hu-man IL-4 have been identified recently by competition experiments employing peptides representing particular segments (Ramanathan et al., 1993) . Whereas these results provide preliminary evidence for a homodimeric IL-4 receptor, the present data strongly suggest a heterodimeric IL-4 receptor system. ·
MATERIALS AND METHODS

Materials
Recombinant human IL-4 and mutant proteins were produced in Escherichia coli and purified as described previously (Weigel et al., 1989; Kruse et al., 1991 Kruse et al., , 1992 Kruse et al., , 1993 . The IL-4 variants used in the present study have been designated as follows: H1Q; C3T; D4N; E9Q; E9K; C24T; E26Q; IQIQ; E41Q; E43Q; C46T; R47Q; R53Q; Y56D; H59Q; K61Q; C65T; R81E; R85Q; R88Q; R88D; W91R; C99T; Jillllil; E.l.Q1K; E114Q; K117Q; M120D; R121D; K123D; K123E; Y124D; Y124G; Y124F; Y124H; Y124K; Y124N; S125D; C127T; C127D; S128D. The number in the designation of the variants indicates the position altered by in vitro mutagenesis. The amino acid originally present in IL-4 is indicated by the first Ietter and the substituted amino acid by the seeond Ietter, both using the one-letter code. Mutant proteins binding to the mAbs with affinities comparable tothat of IL-4 are underlined (Tables 2 and 3 ).
The soluble IL-4 reeeptor (IL-4R..,.) was expressed in CHO cells and purified by affinity chromatography with IL-4 coupled to CNBr-activated Sepharose 4 B (Pharmacia; Kruse et al., 1993) . [3H]thymidine and Na 125 l were obtained from Amersham; N-hydroxysuecinimido Iong-ehain biotin and secondary antibody (goat anti-mouse lgG/alkaline phosphatase conjugate) were from Pierce. RPMI 1640, fetal calf serum and other eell culture reagents were supplied by Biochrom.
Monoclonal antiborlies mAbs to human IL-4 were generated aecording to Galfre and MUstein (1981) and Peters and Baumgarten (1990) . The mAbs 1G1, 4D9, 7D7, and 8F12 were generated in the laboratory of Dr C. Heusser (Andersson et al., 1990) , mAbs 311106 and 3VD4 were established in the laboratories of Prof. W. Sebald and mAb 3B9 was selected by Dr B. Weston and coworkers. The immunization of Balb/c mice was performed using recombinant human IL-4 and Freund's adjuvant. Mouse spieen cells were fused with either NS/0 or PAI myeloma eells. After two weeks, the culture supernatants of fusion products were screened by ELISA using antigencoated microtiter plates or by RIA using sheep anti-mouse Ig coated plates and 125 1-labeled IL-4. The concentration of mAbs purified by established procedures (Harlow and Lane, 1988) was determined spectrophotometrically with an antibody eoneentration of 1 mg/ml yielding an absorbance of 1.35 at 280 nm.
T-cell proliferation assay
Inhibition of T-cell proliferation (measured as detailed in Solari et al., 1989) was expressed as the molar concentration (IC 50 ) of antibody that decreases by 50% the T-cell proliferation activity of recombinant human IL-4. The inhibitory con- 
Protein modiflcations
Biotinylation of reeombinant human IL-4 or IL-4~x was performed according to the manufacturers instructions at a fivefold molar exeess of N-hydroxysuccinimido Iong-ehain biotin over IL-4 or IL-4Rex· Recombinant human IL-4 was radioaetively labeled with 125 1 using the IODO-GEN (1,3,4,6-tetrachloro-3a,6a-diphenyl glycouril) method (Pierce) as described previously (Cabrillat et al., 1987) . The specific radioactivity was determined in a solid phase competition assay as described (Kruse et al., 1993) . The specific radioactivity of 125 1-labeled IL-4 was 0.5-0.8 JlCilpmol IL-4.
ELISA techniques
Binding of mAbs to recombinant human IL-4 and mutant proteins was measured in a competiti ve ELISA (Harlow and Lane, 1988; Hornheck et al., 1991 ) . Flexible assay plates (Falcon MicroTest 111) were coated with streptavidin and blocked. Biotinylated IL-4 (90 pg/ml) was bound to the streptavidin. After washing three times, mAbs at a constant concentration (100-500 ng/ml) were incubated with log2 dilutions of competitor (wild type IL-4 or mutant protein). After three washes, a secondary antibody (anti-mouse IgG/alkaline phosphatase conjugate) diluted 1:2000 was added. The plates were developed using p-nitrophenyl phosphate as substrate and the absorbance at 405 nm was measured using a microplate reader (Dynateeh). From the inhibition curves, the IC 50 value describing the competitor concentration allowing half-maximal binding of mAb to IL-4 on the solid phase was determined. The relative binding of mutant protein was described as IC 50 (variant)IIC 50 (wild-type IL-4). mAb competition groups were established by measuring the competition between two mAbs ( one immobilised on a mierotiter plate, one in solution) for binding of biotinylated IL-4.
Binding of mAbs to recombinant human IL-4 fixed to IL-4Rex was analysed by sandwich ELISA. The microtiter plates were coated with streptavidin and blockedas described for competitive ELISA. Biotinylated IL-4~x was added (100 pg/ml) for 1 h followed by incubation with recombinant human IL-4 (2 Jlg/ml) for 2 h. After three washes, log2 dilutions of mAbs starting with 10 Jlg/ml were added. The following steps were performed as for competitive ELISA.
Spot peptide synthesis and mAb binding assay
Epitope mapping experiments by means of spot peptide synthesis were performed according to the manufaeturer's instructions (Cambridge Research Biochemieals; Frank and Döring, 1988; Blankemeyer-Menge et al., 1990) . Overlapping decapeptides covering the whole amino acid sequence of human IL-4 were synthesized on eellulose paper. The binding of mAb 3B9 to the peptides was analysed using a peroxidase-conjugated anti-mouse lgG (Dianova). The luminescence (Thorpe and Kricka, 1986) of the substrate (luminole) was detected by a Kodak X-OMAT film.
RIA techniques
To test the reactivity of mAbs 1G1, 4D9, 7D7 and 8F12 with wild type IL-4 and mutant proteins, microtiter plates were coated with mAbs (20 J..Lg/ml). 125 1-labeled IL-4 (1 nM) and competitor (wild-type IL-4 or mutant protein, 27 nM) were incubated on the plates for 1 h. The plates were washed three times and bound radioactivity was measured in a gamma counter (Packard Cobra 5005). The values given in Table 3 represent the inhibition of IL-4 binding by competitor, expressed by the following equation:
I= 100 (cpmmax-cpmx)/cpmmax• with I defming the inhibition (%), cpmmiu the maximal bound radioactivity in absence of competitor and cpm,. the bound radioactivity in the presence of competitor.
Receptor-binding assay on T-cells
Binding of 125 1-labeled IL-4 to T-cells was performed as described previously (Kruse et al., 1992) . Briefly, human Tcells prestimulated with phytohemagglutinin were incubated with 0.8 nM 125 1-labeled IL-4 in the presence of various concentrations of mAb (300 nM -1 pM). Separation of the cells from free IL-4 was achieved by centrifugation through silicon oil. The bound radioactivity was determined in a gamma counter (Beckmann). Ki values were calculated using the 
RESULTS
Properties of monoclonal antibodies
All mAbs used in the present study were raised against recombinant human IL-4 produced in E. coli and belong to the subdass lgG1. These mAbs inhibited IL-4-dependent T-cell proliferation ( Fig. 1) , with mAb 3B9 and 8F12 being effective at doses stoichiometric to the applied IL-4 (Kj 60- Table 1 ).
. During spot-blot and Westem-blot analysis, mAbs 3ßiD6, 3B9 and 8F12 reacted equally with native and denatured IL-4 at amounts smaller than 10 ng. mAb 4D9 bound with lower affinity to the denatured IL-4 and the binding of mAbs 3VD4,1G1 and 7D7 could not be measured even with !arge amounts of the denatured protein.
The mAbs could be divided into four groups with overlapping binding regions as determined by competition of two mAbs for IL-4 binding (data not shown), with group I cornprising mAbs 3VD4, 4D9 and 8F12, group II comprising mAbs 1G1 and 707. mAb 3IIID6 represents group III and 3 B9 represents group IV.
Altered binding of certain IL-4 variants to specific mAbs as measured by competitive ELISA Biotinylated IL-4 immobilized on streptavidin-coated wells of a microtiter plate was specifically recognized by the seven mAbs shown in Table 2 . All mAbs, with the exception of 1G1 and 7D7, also bound to IL-4 directly coated onto the plates. The competition between immobilized IL-4 and soluble IL-4 or IL-4 variants for binding to the mAbs could be quantitatively determined by means of an alkaline-phosphatase-linked secondary antibody. Serial dilutions of the soluble proteins yielded dose/inhibition curves as shown in Fig. 2 , from which the concentration effecting 50% inhibition (IC 50 ) could be derived. The examples employing mAb 7D7 shown in The relative IC5o values indicating a loss of binding affmity could thus be classified into four categories as compiled in Table 2 showing one of two independent measurements performed with the indicated mAbs and IL-4 variants. A subset of 12 of the IL-4 variants (see Materials and Methods section; underlined variants) bound during the competitive ELISA to all rnAbs with affinities which differed not measurably from those of IL-4, and these variants are therefore not included in the slightly reduced reactivity to all mAbs (IC 50 of 2-4 ). These variants most likely are structurally disturbed and therefore react to a lower extent ( data not shown). Three variants, i.e.
[C46T], [C99T], [M120D]IL-4, showed a strongly reduced reactivity to all mAbs. The conformation of these variants appears tobe highly impaired (Kruse et al., 1991 (Fig. 4) demonstrates that the side chains affected in these variants are located at the C-terminus and N-terminus near to each other as expected if they were to form part of a common epitope interacting with mAb 3IIID6.
A mAb 3B9, which in this study has the highest potency in inhibiting IL-4 bioactivity, revealed a loss of reactivity with only one of the available variants, i.e. [R81 E]IL-4 (with the exception of the extensively denatured variants). Apparently, the epitope of mAb 3 B9 extends over the N-terminal region of helix C. Binding analysis by means of spot peptides synthesized on paper sheets (Frank and Döring, 1988; Blanken- 
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76 77 78 79 r7 Fig. 3 . A synthetic nested set of IL-4 decapeptides binds specitically to mAb 3B9. The spot-peptide-syntbesis method (BlankemeyerMenge and Frank, 1990 ) was used to synthesize 120 nested decapeptides fixed in spots on a paper. The consecutive peptides, each shifted by one amino acid position, represent tbe whole IL-4 protein sequence. The paperwas incubated with mAb 3B9, and bound 3B9 was detected by a secondary antibody conjugate as shown at the right side of the figure. meyer-Menge et al., ·1990) revealed that partial sequences comprising residues His76, Lys77, Oln78 and Leu79 react specifically with mAb 389 (Fig. 3) . These residues are also located on the N-terminal region of IL-4 helix C.
Reactivity of IL-4 variants with mAb during radioligand binding
The reactivity of the IL-4 variants with mAbs 1G1, 4D9, 7D7 and 8F12 was analysed independently by means of a radioimmunoassay. This experimental setup should be less prone to possible artefacts originating from immobilizing IL-4 to the plastic surface. The results compiled in Table 3 show that the binding of Location of epitope residues on the three-dimensional structure of IL-4
The epitope residues identified during ELISA and RIA form patches on the surface of the IL-4 protein as depicted in Fig. 4 . The largest clusters were identified with mAbs 7D7 and 3IIID6. The surface areas on IL-4 postulated to fonn an epitope have dimensions of approximately 2 nmX2 nm for 7D7 and 1.5X1.5 nm for 3IIID6 (Müller, T., unpublished results) . It is interesting to note that the competition groups of the analysed mAb, as shown in Table 1 , are compatible with the localization of the epitopes. Some overlap appears to exist in the case of Arg81 which might interact with mAbs from different groups (3B9 and 7D7). of 67 nM. The same background Ievels are observed with an isotype matched control mAb. This indicates that the bound receptor blocks the epitopes for these groups of antibodies. In contrast, saturation binding to a high Ievel is found with mAbs 3VD4, 4D9 and 8F12. mAb 3IIID6 also binds, albeit only at higher concentrations, so that saturation probably has not been achieved under the experimental conditions. The bindingwas specifi.c, since it depended completely on bound IL-4 during the assay (data not shown). This indicates that the epitopes of these groups of mAbs are spatially separated from the receptor-binding sites on IL-4, so that a simultaneous binding to IL-4 of both IL-4R..x and mAb is sterically possible.
In a second set of experiments it could be demonstrated that mAbs 3B9, 1G1 and 7D7 inhibited binding of 125 1-labeled IL-4 to the irnmobilized IL-4R.,,. whereas the presence even of a large molar excess of mAbs 3IIID6, 3VD4, 4D9 and 8F12 showed only minor effects ( data not shown), thus confmning the results obtained in the sandwich ELISA.
Influence of mAbs 3B9 and 8F12 on tbe binding of IL-4 to T-cells During the present study, it has been shown that mAbs 3B9 and 8F12 inhibit the IL-4-induced T-cell proliferation at doses nearly stoichiometric to the applied IL-4 concentration (K; 60 pM and 100 pM). The two mAbs exhibited a different effect, however, on binding of IL-4 to the isolated soluble IL-4 receptor. mAb 3B9 blocked binding of IL-4 to ll..-4R,,. completely, whereas mAb 8F12 could bind IL-4 simultaneously with IL-4R..x (Fig. 5) . Thus, it was interesting to analyse how these m.Abs influence IL-4 binding to the functional receptor present on T-cells. As shown in Fig. 6 , m.Ab 3 B9 blocked binding of 125 1-labeled IL-4 to the cellular receptor with an IC 50 of 300 pM, corresponding to a K 1 of 40 pM, whereas for 8F12 a more than 100-fold larger IC 50 of 65 nM was determined (K 1 = 10 nM). Since T-cell proliferation is inhibited at a much lower concentration, it is reasonable to conclude that mAb 8F12 is able to interact with IL-4 bound to the functional receptor on T-cells.
DISCUSSION
The neutralizing monoclonal antiborlies studied during the present experiments discriminate two functionally important sites in human IL-4. One site is recognized by a group of m.Abs which compete with the known receptor protein for IL-4 binding. The second site is detected by those mAbs which are able to bind to IL-4 simultaneously with the receptor protein. The IL-4 variants used in this study have been analysed before with respect to biological activity, physical receptor binding and structural integrity (Kruse et al., 1991 (Kruse et al., , 1992 (Kruse et al., , 1993 and tumed out to be valuable tools in marking the epitopes of all seven mAbs employed in this study. Our mutational epitope scanning approach allowed the mapping of discontinuous or conformational epitopes which are difficult to analyse by other techniques. Moreover, low-affinity mAbs can be analysed. The epitope of one rnAb (3 B9) could be demarcated also by the spot-peptide-synthesis method.
The epitope residues identified during the presented experiments cover major parts of the accessible surfaces of Nearly along the whole surface of helix D, residues were found that contributed to different epitopes, i.e. Glu114, Lys117, Arg121, Tyr124 and Ser128. Finally, one residue on helix B (Arg53) is involved in binding to mAb 7D7. X-ray analyses of antibody/antigen complexes have shown that in the case of Iysozyme (Amit et al., 1986; Sheriff et al., 1987) and influenza virus neuraminidase (Colman et al., 1987) contact areas are approximately 2.5 nmX2 nm and comprise 15-17 amino acid residues. Accordingly, even the IL-4 contact residues identified for mAbs 707 and 3III06 most likely represent only part of the complete epitopes. The present results do not exactly define the borders between the individual epitopes. Competition experiments employing pairs of mAbs in all possible combinations revealed the existence of four groups: two mAbs each from a different group can bind simultaneously to IL-4. Since the competition binding was not analysed quantitatively, it might be possible that the epitopes of mAbs from different groups overlap partially, and that the first mAb attached to IL-4 lowers the binding affinity for the second mAb. The amino acid side chain of Arg81 betonging to both the 3B9 and the 707 epitope might represent such an overlap. · mAbs 3B9 (group IV) and 7D7/1G1 (group II) competed efficiently with IL-4R.," for IL-4 binding. The identified IL-4 epitope residues for the group II and group iV mAbs therefore provide new informations on the binding site of IL-4 for the known receptor protein. The epitope of mAb 7D7 comprises side chains of Glu9 and Arg88. Arg88 also resides in the epitope of mAb 1 G1. Both side chains have been previously identified to interact with IL-4R," (Kruse et al., 1993) , because variants [E9Q/K]IL-4 and [R88Q/D]IL-4 bind with reduced affinities to the receptor (EC 50 variants). The finding that epitope residues of mAb 3B9 are localized at the proximal N-terminal region of helix C, strongly suggests that the IL-4 binding site for IL-4R,x extends to this part of the protein. This conclusion is also in accordance with a recent study (Ramanathan et al., 1993) The most important conclusion drawn from the present results is that the IL-4 binding site for IL-4R.x does not extend to helix 0 and probably does not extend to the N-terminal residues up to Asp4. This conclusion rests on the observation that the group I and III mAbs, whose epitopes are located in these areas, interfere only weakly (3TIID6) or marginally (3VD4, 409, 8F12) with IL-4Rex binding. mAb 8F12 inhibits receptor binding of IL-4 only at more than 1 00-fold higher concentrations than that necessary to inhibit IL-4-dependent T-cell proliferation. This small residual inhibitory activity for IL-4Rex binding may be due to a small overlap between the 8F12 epitope and the receptor-binding site, as the epitope borders are not defined clearly and the binding site for mAb 8F12 may extend onto helix A at undefined positions. The present findings contrast with a recent study on a rat mAb 25 D2 neutralizing human IL-4 bioactivity and receptor binding at an equally low concentration (0.33 nM) and interacting with an IL-4 peptide comprising C-terminal residues 104-129 (Ramanathan et al., 1993) . These results are not necessarily at variance with the present results, since the epitope of rat mAb 25 02 could extend substantially into the binding site of IL-4Re,., most likely onto IL-4 helix A. It is interesting to note that in the human IL-6 system, a group of rnAbs was found which neutralized IL-6 bioactivity without inhibiting IL-6 binding to U266 cells (Brakenhoff et al., 1990 (Brakenhoff et al., , 1992 . Possibly, these mAbs block the binding site on human IL-6 for gp130, but do not interfere with IL-6 binding to the low affinity receptor (IL-6Ra).
What might be the explanation for the IL-4 neutralizing activity of group II and group III mAbs (3VD4, 409, 8F12/ 3III06)? It is now generally agreed that the oligomerisation of receptor subunits represents the critical step leading to receptor activation. Applying an allosteric receptor-oligomerisation model (Schlessinger, 1988) , these mAbs may block an allosteric signalling site on helix D of IL-4, thereby preventing a conformational change which would normally trigger receptor oligomerisation. Although such a mechanism cannot be formally excluded, severallines of recent evidence favour a sequential direct receptor oligomerisation via multiple binding sites on the IL-4 Iigand. IL-4 is structurally related to growth hormone and the IL-4 receptor belongs to the same family of receptors as the growth-hormone-binding protein. Similar to the human growth hormone, IL-4 might first interact with IL-4Rx via its binding site provided by residues on helices A and C. This complex creates an interface including signalling residues on IL-4 helix D for the attachment of a second receptor subunit (Müller et al., 1994 ). An analysis of the charge distribution on human IL-4 and IL4Re,. (Demchuk, E., unpublished results) suggest the formation of a heterodimeric receptor, i.e. the second receptor sub-unit is not IL-4Rex· The recent finding of cross competition between human ~-4 and human ~-13 for binding to TF1 cells (Zurawski et al., 1993) would be consistent with a second receptor subunit common to the IL-4 and IL-13 systems. However, it could be also visualized that an IL-13-binding protein interacts with a hetero-dimeric or homodimeric IL-4 receptor complex, similar to the complex of ciliary neurotrophic factor/ciliary neurotrophic-factor-binding protein interacting with a heterodimeric receptor complex (Davis et al., 1993) .
Recent findings suggest that the y-chain of the interleukin-2 receptor is a functional component of the IL-4 receptor (and also the interleukin-7 receptor) in murine as weil as in human cells Kondo et al., 1993; Noguchi et al., 1993) . Thus, it is a reasonable assumption that the signalling site on helix D of human IL-4 interacts with this comrnon y-receptor subunit. lt can be easily visualised that mAbs directed against the signalling site block binding of the common y chain and thereby inhibit the biological activity of IL-4 but not IL-4Rex binding.
The present results stress the importance of C-terminal residues and the surface of helix D for IL-4 bioactivity. The present study and a previous study reveal, however, that this region is not involved in binding to the known IL-4 receptor as often discussed (Le et al., 1991; Morrison and Leder, 1992; Bamborough et al., 1993; Wlodawer et al., 1993; Ramanathan et al., 1993) . It can be visualized that the two types of neutralizing anti-IL-4 mAbs (blocking or not blocking cell-surface receptor binding) behave differently in vivo. Possibly, organ distribution, clearance route and half life are different for a mAb binding to soluble IL-4 only and for a mAb also reacting with cell-bound IL-4.
